Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone

J Hosp Infect. 2020 Jan;104(1):33-39. doi: 10.1016/j.jhin.2019.07.014. Epub 2019 Jul 29.

Abstract

Background: Pseudomonas aeruginosa is a major bacterial pathogen responsible for hospital-acquired infections. Although its epidemiology is considered as non-clonal, certain international high-risk multidrug-resistant clones have been recognized.

Aim: From the first report of an intra-hospital outbreak due to an SHV2a-producing P. aeruginosa strain, to describe the emergence of a new ST235-specific lineage harbouring this rare extended-spectrum β-lactamase (ESBL).

Methods: Between May and October 2018, four patients hospitalized in the cardiovascular intensive care unit of a French teaching hospital were infected by a multidrug-resistant P. aeruginosa isolate. Serotype and antimicrobial susceptibility were tested; multi-locus sequence type (MLST), core genome MLST, and resistome were determined through whole genome sequencing. A phylogenetic analysis based on single nucleotide polymorphism was performed using available ST235 genomes.

Findings: The four strains were susceptible to colistin, ciprofloxacin, ceftazidime-avibactam, and ceftolozane-tazobactam. blaSHV2a was identified in each genome of this ST235-O11 serotype cluster that showed an identical cgMLST profile (0-2 out of 4162 different alleles). The phylogenic analysis of 162 ST235 genomes showed that only four other strains harboured a blaSHV2a, originating from France and USA, clustering together although being different from the outbreak strains.

Conclusions: Among the ST235 P. aeruginosa strains, a sub-lineage sharing a common genetic background and harbouring the blaSHV2a ESBL seems to emerge from different locations, yielding secondary local outbreaks.

Keywords: ESBL; Outbreak; Pseudomonas aeruginosa; SHV2a; ST235.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Azabicyclo Compounds / pharmacology
  • Bacterial Proteins / genetics
  • Ceftazidime / pharmacology
  • Cephalosporins / pharmacology
  • Ciprofloxacin / pharmacology
  • Colistin / pharmacology
  • Cross Infection / epidemiology
  • Cross Infection / microbiology*
  • Disease Outbreaks / prevention & control
  • Disease Outbreaks / statistics & numerical data
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Female
  • France / epidemiology
  • Humans
  • Microbial Sensitivity Tests / methods
  • Multilocus Sequence Typing / methods
  • Polymorphism, Single Nucleotide / genetics
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / genetics*
  • Pseudomonas aeruginosa / isolation & purification
  • Tazobactam / pharmacology
  • beta-Lactamases / drug effects
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Bacterial Proteins
  • Cephalosporins
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • ceftolozane, tazobactam drug combination
  • Ciprofloxacin
  • Ceftazidime
  • beta-lactamase SHV-2a
  • beta-Lactamases
  • Tazobactam
  • Colistin